A Universal Single-Activated-Dual-Release Vehicle: Enabling Synergistic Antitumor Therapy

Area of Science:

• Biomedical Engineering
• Oncology
• Drug Delivery Systems

Background:

• Combination therapy offers potential for treating malignant tumors.
• Effective drug release timing and location are crucial for maximizing combination therapy efficacy.
• Current strategies face challenges in achieving precise and simultaneous release of multiple therapeutic agents.

Purpose of the Study:

• To develop a universal single-activated-dual-release platform for combination cancer therapy.
• To demonstrate a proof-of-concept synergistic therapy (CyI-Cbl-NTR) activated by nitroreductase (NTR).
• To enable the combined use of photodynamic therapy and chemotherapy.

Main Methods:

• Utilized 1,4- and 1,6-elimination behaviors for drug release.
• Designed a platform activated by specific stimulants like NTR.
• Developed a synergistic therapy releasing a photosensitizer (CyI-OH) and a DNA alkylating agent (chlorambucil/Cbl).
• Conducted in vitro and in vivo experiments to validate the strategy.

Main Results:

• The CyI-Cbl-NTR system was selectively activated by NTR.
• The platform successfully released both CyI-OH and Cbl.
• Demonstrated significant combined therapeutic effects in both in vitro and in vivo models.
• Validated the feasibility of the activatable dual-release strategy.

Conclusions:

• The proposed platform offers a promising approach for activatable synergistic cancer therapy.
• This strategy allows for controlled and simultaneous release of multiple therapeutic agents.
• The findings support the future development of advanced combination therapies for malignant tumors.